Clinical Trial

A Phase I Study of JSB462 (Luxdegalutamide) in Japanese Patients With Metastatic Prostate Cancer

Active, Not Recruiting Phase 1
View on ClinicalTrials.gov →
Summary
This Phase I study aims to evaluate the safety, tolerability and PK of JSB462 in Japanese patients with metastatic prostate cancer.
Protocol Amendment History 4 changes
critical Trial status changed: Recruiting → Active, Not Recruiting 2026-07-03
notable Enrollment reduced: 15 -> 6 participants 2026-07-03
notable Primary completion moved earlier: 2027-06-18 -> 2027-01-29 2026-06-26
minor Completion moved earlier: 2027-06-18 -> 2027-01-29 2026-06-26
Trial Details
NCT Number NCT07174063
Lead Sponsor Novartis Pharmaceuticals
Conditions Metastatic Prostate Cancer (mCRPC)
Enrollment 6 participants
Start Date 2025-11-26
Primary Completion 2027-01-29 (estimated)
Study Completion 2027-01-29 (estimated)
Updated on ClinicalTrials.gov 2026-07-08